Abstract B080: Assessment of the molecular mechanisms of a protective variant for breast cancer in Latinas
Valentina A. Zavala(San Francisco General Hospital), Laura Fejerman(University of California, San Francisco), JE Abugattas(Instituto Nacional de Enfermedades Neoplásicas), Tatiana Vidaurre(The University of Texas MD Anderson Cancer Center), Carlos A. Castañeda(Instituto Nacional de Enfermedades Neoplásicas), Silvia P. Neciosup(Instituto Nacional de Enfermedades Neoplásicas), Jovanny Zabaleta(Stanley Foundation), Henry Gómez(National Cancer Center), Jeannie Navarro Vásquez(Instituto Nacional de Enfermedades Neoplásicas), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Hugo Fuentes(Instituto Nacional de Enfermedades Neoplásicas), Fernando Valencia(Instituto Nacional de Enfermedades Neoplásicas), Claudia Monge(Instituto Nacional de Enfermedades Neoplásicas), Zaida Morante, Lizeth I. Tamayo(University of Illinois Chicago), Mónica Calderón(Instituto Nacional de Enfermedades Neoplásicas), Katie M. Marker(Berkeley College)
Cited by 0
Related Papers
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483